ALKERMES, INC.
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT06555783
- Locations
- 🇦🇺
Alkermes Investigator Site, Bedford Park, South Australia, Australia
🇺🇸Alkermes Investigational Site, Peoria, Illinois, United States
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT06358950
- Locations
- 🇺🇸
Alkermes Investigational Site, The Woodlands, Texas, United States
🇦🇺Alkermes Investigator Site, Bedford Park, South Australia, Australia
Study of the Breast Milk Pharmacokinetics of Olanzapine and Samidorphan
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05547100
- Locations
- 🇺🇸
Alkermes Investigator Site, Las Vegas, Nevada, United States
Study to Evaluate Weight Gain As Assessed by Change in BMI Z-score in Pediatric Subjects with Schizophrenia or Bipolar I Disorder
- Conditions
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT05303064
- Locations
- 🇺🇸
Alkermes Investigational Site, Kinston, North Carolina, United States
🇲🇽Alkermes Investigator Site, Monterrey, Mexico
Phase 1 ALKS 1140 in Healthy Adults
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2022-09-02
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05019105
- Locations
- 🇦🇺
Alkermes Clinical Investigative Site, Brisbane, Australia
Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I Disorder
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT04987658
- Locations
- 🇺🇸
Alkermes Investigational Site, Decatur, Georgia, United States
🇺🇸Alkermes Clinical Investigative Site, Cincinnati, Ohio, United States
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 236
- Registration Number
- NCT04987229
- Locations
- 🇲🇽
Alkermes Investigational Site, Culiacán, Sinaloa, Mexico
A 28 Day Parallel Group Study to Assess the Effects of RDN-929
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT03963973
- Locations
- 🇳🇱
Brain Research Center, Amsterdam, Netherlands
🇳🇱QPS Netherlands B.V., Leeuwarden, Netherlands
Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)
- Conditions
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2023-02-02
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 338
- Registration Number
- NCT03919994
- Locations
- 🇺🇸
Alkermes Investigational Site, Salt Lake City, Utah, United States
Single and Multiple Ascending Dose and Food Effect PK Study in Healthy Adult and Elderly Subjects
- Conditions
- Interventions
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT03668314
- Locations
- 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands